Next generation antithrombotic therapy: Focus on antisense therapy against coagulation factor xi

Seminars in Thrombosis and Hemostasis

Volumn 41, Issue 2, 2015, Pages 255-262

  Lippi, Giuseppe ^a   Harenberg, Job ^b   Mattiuzzi, Camilla ^c   Favaloro, Emmanuel J ^d  

^a ACADEMIC HOSPITAL OF PARMA   (Italy)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Trento General Hospital   (Italy)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

anticoagulant therapy; antisense therapy; factor XI; thrombosis; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ANTISENSE OLIGONUCLEOTIDE; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 11; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MESSENGER RNA; WARFARIN; ANTISENSE OLIGODEOXYNUCLEOTIDE; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ANTISENSE THERAPY; ARTICLE; BLEEDING; COST EFFECTIVENESS ANALYSIS; HUMAN; KNEE SURGERY; MESSENGER RNA SYNTHESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN SYNTHESIS; VALIDATION STUDY; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; METABOLISM; VENOUS THROMBOSIS;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; FACTOR XI; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; VENOUS THROMBOSIS; WARFARIN;

EID: 84923922528     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0035-1546466     Document Type: Article

References (40)

1. Dias N., Stein C. A. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther: 2002; 1 5 347 355
2. Bennett C. F., Swayze E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol: 2010; 50 259 293
3. Lippi G., Favaloro E. J. Antisense therapy in the treatment of hypercholesterolemia. Eur J Intern Med: 2011; 22 6 541 546
4. Castanotto D., Stein C. A. Antisense oligonucleotides in cancer. Curr Opin Oncol: 2014; 26 6 584 589
5. Mourich D. V., Marshall N. B. Antisense approaches to immune modulation for transplant and autoimmune diseases. Curr Opin Pharmacol: 2005; 5 5 508 512
6. Falzarano M. S., Passarelli C., Ferlini A. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy. Nucleic Acid Ther: 2014; 24 1 87 100
7. Gauvreau G. M., Boulet L. P., Cockcroft D. W., et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med: 2008; 177 9 952 958
8. Lu X., Yu Q., Binder G. K., et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol: 2004; 78 13 7079 7088
9. de Jong Y. P., Jacobson I. M. Antisense therapy for hepatitis C virus infection. J Hepatol: 2014; 60 1 227 228
10. Lippi G., Franchini M. Pathogenesis of venous thromboembolism: when the cup runneth over. Semin Thromb Hemost: 2008; 34 8 747 761
11. Duga S., Salomon O. Congenital factor XI deficiency: an update. Semin Thromb Hemost: 2013; 39 6 621 631
12. Vercauteren E., Gils A., Declerck P. J. Thrombin activatable fibrinolysis inhibitor: a putative target to enhance fibrinolysis. Semin Thromb Hemost: 2013; 39 4 365 372
13. Salomon O., Steinberg D. M., Zucker M., Varon D., Zivelin A., Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb Haemost: 2011; 105 2 269 273
14. Löwenberg E. C., Meijers J. C., Monia B. P., Levi M. Coagulation factor XI as a novel target for antithrombotic treatment. J Thromb Haemost: 2010; 8 11 2349 2357
15. Zhang H., Löwenberg E. C., Crosby J. R., et al. Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk. Blood: 2010; 116 22 4684 4692
16. Que Liu E. D., Claudette B., Shuting X., et al. ISIS-FXIRx, a novel and specific antisense inhibitor of factor XI, caused significant reduction in FXI antigen and activity and increased aPTT without causing bleeding in healthy volunteers. Blood: 2011; 118 209
17. Younis H. S., Crosby J., Huh J. I., et al. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys. Blood: 2012; 119 10 2401 2408
18. Crosby J. R., Marzec U., Revenko A. S., et al. Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol: 2013; 33 7 1670 1678
19. Yau J. W., Liao P., Fredenburgh J. C., et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood: 2014; 123 13 2102 2107
20. van Montfoort M. L., Kuijpers M. J., Knaup V. L., et al. Factor XI regulates pathological thrombus formation on acutely ruptured atherosclerotic plaques. Arterioscler Thromb Vasc Biol: 2014; 34 8 1668 1673
21. Büller H. R., Bethune C., Bhanot S., et al. the FXI-ASO TKA Investigators. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med: 2015; 372 3 232 240
22. Raskob G. E., Angchaisuksiri P., Blanco A. N., et al. ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Semin Thromb Hemost: 2014; 40 7 724 735
23. Dahl O. E., Harenberg J., Wexels F., Preissner K. T. Arterial and venous thrombosis following trauma and major orthopedic surgery: molecular mechanisms and strategies for intervention. Semin Thromb Hemost: 2015; 41 2 141 145
24. Zolfaghari S., Harenberg J., Froelich L., Wehling M., Weiss C. Development of a tool to identify patients' preference for vitamin K antagonist or direct oral anticoagulant therapy. Semin Thromb Hemost: 2014; 40 1 121 128
25. Lippi G., Favaloro E. J. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med: 2015; 53 2 185 197
26. Favaloro E. J., Lippi G. The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb): 2012; 22 3 329 341
27. Riva N., Ageno W. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost: 2015; 41 2 178 187
28. Agnelli G., Prandoni P., Di Minno G., et al. Thromboprophylaxis with low molecular weight heparins. An assessment of the methodological quality of studies. Semin Thromb Hemost: 2015; 41 2 113 132
29. Favaloro E. J., Lippi G., Koutts J. Laboratory testing of anticoagulants: the present and the future. Pathology: 2011; 43 7 682 692
30. Lippi G., Favaloro E. J., Mattiuzzi C. Combined administration of antibiotics and direct oral anticoagulants: a renewed indication for laboratory monitoring? Semin Thromb Hemost: 2014; 40 7 756 765
31. Tripodi A., Di Iorio G., Lippi G., Testa S., Manotti C. Position paper on laboratory testing for patients taking new oral anticoagulants. Consensus document of FCSA, SIMeL, SIBioC and CISMEL1). Clin Chem Lab Med: 2012; 50 12 2137 2140
32. Harenberg J., Kraemer S., Du S., et al. Determination of direct oral anticoagulants from human serum samples. Semin Thromb Hemost: 2014; 40 1 129 134
33. Harenberg J., Du S., Krämer S., Weiss C., Krämer R., Wehling M. Patients' serum and urine as easily accessible samples for the measurement of non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost: 2015; 41 2 228 236
34. Bane C. E. Jr, Gailani D. Factor XI as a target for antithrombotic therapy. Drug Discov Today: 2014; 19 9 1454 1458
35. Bird J. E., Smith P. L., Wang X., et al. Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait. Thromb Haemost: 2012; 107 6 1141 1150
36. Flaumenhaft R. Making (anti)sense of factor XI in thrombosis. N Engl J Med: 2015; 372 3 277 278
37. Morrissey J. H. Targeting factor XI to prevent thrombosis. Arterioscler Thromb Vasc Biol: 2013; 33 7 1454 1455
38. Buller H. R., Cohen A. T., Davidson B., et al. van Gogh Investigators. Extended prophylaxis of venous thromboembolism with idraparinux. N Engl J Med: 2007; 357 11 1105 1112
39. Harenberg J., Vukojevic Y., Mikus G., Joerg I., Weiss C. Long elimination half-life of idraparinux may explain major bleeding and recurrent events of patients from the van Gogh trials. J Thromb Haemost: 2008; 6 5 890 892
40. Crooke S. T. Antisense Drug Technology: Principles, Strategies, and Applications. 2nd ed. New York, NY CRC Press: 2007